SAGE Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -788.06% compared to Sage Therapeutics's net margin of 11.99%. Sage Therapeutics's return on equity of -48.2% beat Johnson & Johnson's return on equity of 20.88%.

Sage Therapeutics has a consensus price target of $24.39, signalling upside risk potential of 64.23%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.49%. Given that Sage Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Sage Therapeutics is more attractive than Johnson & Johnson.

Sage Therapeutics has a beta of 0.869, which suggesting that the stock is 13.067% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.33% to investors and pays a quarterly dividend of $1.24 per share. Sage Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sage Therapeutics quarterly revenues are $11.9M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Sage Therapeutics's net income of -$93.6M is lower than Johnson & Johnson's net income of $2.7B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 3.11x versus 4.04x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Lifecore Biomedical has a net margin of -788.06% compared to Sage Therapeutics's net margin of -18.7%. Sage Therapeutics's return on equity of -48.2% beat Lifecore Biomedical's return on equity of 475.5%.

Sage Therapeutics has a consensus price target of $24.39, signalling upside risk potential of 64.23%. On the other hand Lifecore Biomedical has an analysts' consensus of -- which suggests that it could grow by 5.26%. Given that Sage Therapeutics has higher upside potential than Lifecore Biomedical, analysts believe Sage Therapeutics is more attractive than Lifecore Biomedical.

Sage Therapeutics has a beta of 0.869, which suggesting that the stock is 13.067% less volatile than S&P 500. In comparison Lifecore Biomedical has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.212%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifecore Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Lifecore Biomedical pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $11.9M, which are smaller than Lifecore Biomedical quarterly revenues of $37.9M. Sage Therapeutics's net income of -$93.6M is lower than Lifecore Biomedical's net income of -$7.1M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Lifecore Biomedical's PE ratio is 152.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 3.11x versus 2.09x for Lifecore Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of -788.06% compared to Sage Therapeutics's net margin of -97.47%. Sage Therapeutics's return on equity of -48.2% beat Outset Medical's return on equity of -145.43%.

Sage Therapeutics has a consensus price target of $24.39, signalling upside risk potential of 64.23%. On the other hand Outset Medical has an analysts' consensus of $5.79 which suggests that it could grow by 253.98%. Given that Outset Medical has higher upside potential than Sage Therapeutics, analysts believe Outset Medical is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.869, which suggesting that the stock is 13.067% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $11.9M, which are smaller than Outset Medical quarterly revenues of $28.7M. Sage Therapeutics's net income of -$93.6M is lower than Outset Medical's net income of -$27.9M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 3.11x versus 0.50x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Poseida Therapeutics has a net margin of -788.06% compared to Sage Therapeutics's net margin of 28.2%. Sage Therapeutics's return on equity of -48.2% beat Poseida Therapeutics's return on equity of -66.05%.

Sage Therapeutics has a consensus price target of $24.39, signalling upside risk potential of 64.23%. On the other hand Poseida Therapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 0.11%. Given that Sage Therapeutics has higher upside potential than Poseida Therapeutics, analysts believe Sage Therapeutics is more attractive than Poseida Therapeutics.

Sage Therapeutics has a beta of 0.869, which suggesting that the stock is 13.067% less volatile than S&P 500. In comparison Poseida Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Poseida Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Poseida Therapeutics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $11.9M, which are smaller than Poseida Therapeutics quarterly revenues of $71.7M. Sage Therapeutics's net income of -$93.6M is lower than Poseida Therapeutics's net income of $20.2M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Poseida Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 3.11x versus 6.09x for Poseida Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.